Corrales L, McWhirter SM, Dubensky TW Jr, Gajewski TF. Prevalence and Frequency of Eosinophil Testing in Patients with Asthma. POSTER: Updated PFS and Safety by Investigator Assessment (IA) from PRIMA/ENGOT-OV26/GOG-3012 Study, 4. [Poster No. Analysis of Co-Resistance Among Escherichia coli Urine Isolates From Female Outpatients in the United States. Neutrophil extracellular traps and CXCR2 antagonism in chronic obstructive pulmonary disease: A pilot randomized control study. temperature excursion. Analysis of Co-Resistance Among Klebsiella pneumoniae Urine Isolates From Female Outpatients in the United States. 8. (Poster No. [Poster No. CAPTAIN Study: Daily Digital Spirometry and Symptom Data for Once-Daily, Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Asthma. GSK3174998 is a humanized immunoglobulin 1 (IgG1) OX40 agonist antibody that can enhance the proliferation and survival of CD4+ and CD8+ T cells and deplete tumor-infiltrating regulatory T cells via antibody-dependent cell cytotoxicity or phagocytosis. Retrospective Analyses of SoC and Treatment Patterns Among Patients with RRMM in Europe [Poster not available for viewing due to copyright restrictions], 3. Assessment of Peak Inspiratory Flow Rate in Patients With Chronic Obstructive Pulmonary Disease: Impact on Dose Delivery and Relationship With Response to Fluticasone Furoate/Umeclidinium/Vilanterol Triple Therapy. Trumemba Viable Non- viable . Impact of the COVID-19 Pandemic on Dispensing of Respiratory Therapies Among Patients with Chronic Obstructive Pulmonary Disease (COPD) in the United States: A Population-Based Study. Based on rounding rules, temperatures between 1.5 C and 8.4 C (34.7 F-47.2 F) are within the recommended range for this vaccine. POSTER: DREAMM-2: Single-Agent Belantamab Mafodotin (GSK2857916) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) and Renal Impairment. Modeling of short-acting beta agonist (SABA) use: effect of symptom control in patients with moderate-severe asthma requiring rescue medication. CAPTAIN Study: Simultaneous Step-up to High Dose Fluticasone Furoate and Addition of Umeclidinium for the Treatment of Inadequately Controlled Asthma. Halpin DMG, Worsley S, Ismaila AS, et al. Prevalence and Frequency of Eosinophil Testing in Patients with Asthma. POSTER: Pharmacokinetics and Safety Following a Single Oral Dose of Niraparib in Patients with Moderate Hepatic Impairment, 5. Dasgupta, I et al. ag the affected vaccines and place a label on them saying "DO NOT USE." Do not 6. 1. Amsterdam, Netherlands: TESARO Bio Netherlands BV; 2019. Simply select from the required information below. Poster No. Encore: DREAMM-3: Phase III, Open-Label, Randomized Study of Single-Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Relapsed/Refractory Multiple Myeloma (RRMM) [Publication only], 13. Preliminary Safety, Efficacy, and Pharmacokinetic/Pharmacodynamic Characterization from GARNET, a Phase 1/2 Clinical Trial of the Anti PD 1 Monoclonal Antibody, Dostarlimab, in Patients with Recurrent or Advanced MSI H and MSS Endometrial Cancer (EC), For a copy of a poster please call 1-877-475-6448, 1. POSTER: Factors Affecting PARP Inhibitor Use as Maintenance Treatment in Platinum-Sensitive Recurrent Ovarian Cancer, 2. ASCEND-TD: A Randomized, Double-Blind, Active-Controlled Study of Daprodustat Administered Three-Times-Weekly in Hemodialysis Patients, 3. Davitte J, DeBarmore B, Hinds D, et al. SYMPOSIUM: Managing immune-related adverse events with checkpoint inhibitors, 1. Georgiev H, Ravens I, Papadogianni G, Bernhardt G. Coming of age: CD96 emerges as modulator of immune responses. 2. IF TEMPERATURES ARE OUT OF RANGE, TAKE IMMEDIATE ACTION! Sorry to interrupt Close this window. 1. POSTER: VOCAL (Views of Ovarian Cancer patients-how maintenance therapy Affects their Lives) study: patient preference for treatment formulation and administration (IGCS 2022), 2. Chandler R et al. ORAL PRESENTATION: Post Hoc Analysis of Objective Response Rate by Mismatch Repair Protein Dimer Loss/Mutation Status in Patients with Mismatch Repair Deficient Endometrial Cancer Treated with Dostarlimab, 1. Poster with video: Long-term Treatment Outcome With Niraparib in Patients With Recurrent Ovarian Cancer: Results From the ENGOT-OV16/NOVA Trial, 3. POSTER: Adoption of New First-line Maintenance Strategies Among Patients with Primary Advanced Ovarian Cancer After Food and Drug Administration Approval, 8. P1458. Nat Med. Poulard C, Corbo L, Le Romancer M. Protein arginine methylation/demethylation and cancer. By clicking this link, you will be taken to a website that is independent from GSK. Lan Y, Zhang D, Xu C, et al. 2. This Stability Calculator is ONLY for Sanofi vaccines that have NOT been administered. NY-ESO-1 based immunotherapy of cancer: current perspectives. Epidemiology of Eosinophilic Granulomatosis with Polyangiitis (EGPA) and Hypereosinophilic Syndrome (HES) in Germany: A Claims Database Study. P1481. Electronic address: didier.clenet@sanofi.com. Poster No. Efficacy of Mepolizumab in Patients with Eosinophilic Granulomatosis with Polyangiitis and a Vasculitic Phenotype. Recent advances in targeting protein arginine methyltransferase enzymes in cancer therapy. Fiore. ORAL PRESENTATION: Updated Results from the Momentum Phase 3 Study of Momelotinib (MMB) Versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor, 3. Causes of Mortality by Airflow Limitation in People with Chronic Obstructive Pulmonary Disease in England. Analysis of a Composite Endpoint of Exacerbation and Early Study Treatment Withdrawal in Symptomatic Patients With COPD Free of Inhaled Corticosteroids: A Post Hoc Analysis of the EMAX Trial. Risk of death and chronic obstructive pulmonary disease (COPD) hospitalization with fluticasone furoate-containing therapy: Post hoc subgroup analysis from the SUMMIT trial in patients with COPD and a history of exacerbation. Impact of the COVID-19 Pandemic on Dispensing of Respiratory Therapies Among Patients with Chronic Obstructive Pulmonary Disease (COPD) in the United States: A Population-Based Study. 2. www.fda.gov/medwatch. Steinfeld J, Roufosse F, Kahn JE, et al. CAPTAIN Study: Simultaneous Step-up to High Dose Fluticasone Furoate and Addition of Umeclidinium for the Treatment of Inadequately Controlled Asthma. 5. Poster No. OX40 agonists and combination immunotherapy: putting the pedal to the metal. Hemoglobin Efficacy and Cardiovascular Safety Data from the ASCEND-ND, -D, and -ID Trials. POSTER: Effectiveness and Safety of Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma in Real-Life Setting: The ALFA Study, 6. Describing asthma control and adherence in patients with extended Salford Lung Study (Ex-SLS) prescribed inhaled corticosteroids/long-acting beta agonists (ICS/LABAs). Niraparib + Pembrolizumab (Pembro) Versus Placebo + Pembro 1L Maintenance Therapy in Advanced NSCLC: ZEAL-1L Phase III Study, 2. Safety and Tolerability of Single-Agent Belantamab Mafodotin in Heavily Pretreated Patients With Relapsed/Refractory Multiple Myeloma: Pooled Data From DREAMM-1 and DREAMM-2 [Poster not available for viewing due to copyright restrictions], 5. 4. This site is intended for US Healthcare Professionals. Name of the person completing the report. P813; Abstract A4302]. Desrosiers M, Diamant Z, Castelnuovo P, et al. Patient-Reported Experiences During and Following Treatment with Belantamab Mafodotin (Belamaf) for Relapsed/Refractory Multiple Myeloma (RRMM) in the DREAMM-2 Study, 3. POSTER: Progression-free survival (PFS) and overall survival (OS) in advanced/recurrent (AR) mismatch repair deficient/microsatellite instabilityhigh or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC) treated with dostarlimab in the GARNET study, 5. Singh AK, et al. Seo J, Zhang S, Krucien N, et al. GSK3745417 is a synthetic STING agonist that is being investigated as a monotherapy and in combination with pembrolizumab in relapsed/refractory solid tumors. Cho E-Y, Cho J-E, Jang S-H, et al. PD-L1 is expressed by many tumor types and is linked to poor clinical outcomes in a variety of cancers. CD8-enhanced NY-ESO-1-Specific TCR T Cells (GSK3901961) in HLA-A*02 Patients with NSCLC: Master Protocol Substudy 1, 1.ORAL PRESENTATION:DREAMM-6: Safety and Tolerability of Belantamab Mafodotin in Combination with Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM). Benefits of Initiating Single-Inhaler Triple Therapy (SITT) with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus Multiple-Inhaler Triple Therapy (MITT) Among Medicare Advantage with Part D Beneficiaries with Chronic Obstructive Pulmonary Disease (COPD). A Prospective Evaluation of Tolerability of Niraparib Dosing Based Upon Baseline Body Weight and Platelet Count: Blinded Pooled Interim Safety Data From the PRIMA/ENGOT OV26/GOG 3012 Study, 3. Patient and Physician Preferences for Treatments of Anemia in Chronic Kidney Disease: Insights from the Qualitative Pilot of a Choice Experiment, 7. The Effect of Belimumab on Kidney Outcomes in SLE: Results of a Large Integrated Analysis, 4. POSTER: Year 4 Observational Follow up of Belimumab Safety (Mortality and Malignancies) in Patients with SLE who Completed a Phase 4, 52-week, Randomised, Double-blind Placebo-controlled Safety, 4. Genetic variants do not predict acute COPD exacerbations or treatment response to fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) and its components. Bintrafusp alfa is a bifunctional fusion protein composed of the extracellular domain of the human transforming growth factor receptor II (TGF-RII or TGF- trap") fused via a flexible linker to the C-terminus of each heavy chain of the IgG1 antibody blocking PD-L1. Moore WC, Kornmann O, Humbert M, et al. POSTER: Meta-analysis of pazopanib and trabectedin in 2L+ metastatic synovial sarcoma (2L+ mSS), 5. Immunotherapy. Maximal Change in Erythropoietin in Hemodialysis Patients Receiving Daprodustat or Epoetin Alfa in the ASCEND-TD Trial, 9. POSTER: Belantamab Mafodotin detection by protein electrophoresis: Assessing interference for defining clinical response, 2. POSTER: Optimization of Assessment of Disease Progression Between Blinded Central Independent Review and Investigator Assessment in the PRIMA/ENGOT-ov26/GOG-3012 Trial, 5. Silver J, Bogart M, Molfino N, et al. Kerwin EM, Bjermer L, Maltais F, et al. Can Recombinant Zoster Vaccine Administration Decrease the Use of HZ-Related Pain Medication Across Randomized Controlled Studies? PUBLICATION ONLY: Study Design of A Global Molecular Disease Characterization Initiative (MDCI) in Oncology Clinical Trials, 1. 2. The products discussed may have different product labeling in different countries. POSTER: First-line Maintenance Among Advanced Ovarian Cancer Patients in The US Oncology Network: A Real-world Retrospective Cohort Study, 9. PO0465, 4. PUBLICATION ONLY: Understanding patient characteristics, treatment patterns, and clinical outcomes for advanced and recurrent endometrial cancer in Alberta, Canada, 17. POSTER: Immuno-PET monitoring of CD8 + T cell infiltration post anti-ICOS agonist antibody treatment alone and in combination with PD-1 blocking antibody using a 89Zr anti-CD8+ mouse minibody in EMT 6 syngeneic tumor mouse, 4. Epidemiology of Eosinophilic Granulomatosis with Polyangiitis (EGPA) and Hypereosinophilic Syndrome (HES) in Germany: A Claims Database Study. POSTER: Evaluation of an Individualized Starting Dose of Niraparib in the PRIMA/ENGOT-OV26/GOG-3012 Study, 4. Rationale for anti-OX40 cancer immunotherapy. 1. T-cell immunoglobulin and mucin domain-3 (TIM-3), is a negative regulatory checkpoint molecule that regulates T-cell exhaustion, dampens the antitumor immune response, and may promote tumor cell migration and invasion. POSTER: Systematic literature review of prognostic factors associated with overall survival among advanced synovial sarcoma and myxoid/round cell liposarcoma subjects, 3. PO0487, 1. Views of US pulmonologists on the prevalence of uncontrolled asthma, treatment decisions and the role of treatable traits: results from the CHEST Pulse Surveys. Safety Profile of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Populations: An Overview of 6 Trials, 9. A phase I study of molibresib (GSK525762), a selective bromodomain (BRD) and extra terminal protein (BET) inhibitor: results from part 1 of a phase I/II open-label single-agent study in subjects with non-Hodgkins lymphoma (NHL), 3. CAPTAIN Study: Daily Digital Spirometry and Symptom Data for Once-Daily, Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Asthma. Pivotal DREAMM-2 Study: Single-Agent Belantamab Mafodotin (Belamaf; GSK2857916) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to Proteasome Inhibitors, Immunomodulatory Agents, and Refractory and/or Intolerant to Anti-CD38 Monoclonal Antibodies (mAbs), Including Subgroups with Renal Impairment (RI) and High-Risk (HR) Cytogenetics, 3. Blake SJ, Stannard K, Liu J, et al. 12. Busse W, Chupp G, Stanaland M, et al. This can . Development of a Conceptual Model to Understand Disease Burden in Patients with Systemic Lupus Erythematosus and Long-Term Organ Damage, 3. 1. 1. 1. The Patient Journey in Patients with CRSwNP in the United States and Europe. Lu E, Mu G, Alfonso-Cristancho R. Symposium: The Evolving Therapeutic Landscape in Relapsed/Refractory Multiple Myeloma, 1. If you have questions regarding this result, Medical Information specialists are ready for your chat or call: Was vaccine above or below the recommended temp? GSK3359609 is an IgG4 ICOS agonist antibody that is designed to enhance T-cell function and enable antitumor responses without depletion of ICOS-expressing cells. ORAL PRESENTATION: Bone Marrow Fibrosis Changes Do Not Correlate with Efficacy Outcomes in Myelofibrosis: Analysis of More Than 300 JAK Inhibitor-Nave Patients Treated with Momelotinib or Ruxolitinib, 1. Visit Epidemiological Modelling to Estimate the Number of US Patients With Multiple Myeloma at Different Lines of Treatment, 2. Hosking L, Yeo A, Hoffman J, et al. Oncotarget. ORAL PRESENTATION: MOMENTUM: Phase 3 Randomized Study of Momelotinib (MB) versus Danazol (DAN) in Symptomatic and Anemia Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor, 2. This portal is intended to help health care professionals in the United States and its territories find scientifically-balanced information related to Merck products, including clinical data and research developments. Treatment Patterns and Disease Burden of Triple Therapy in Asthma. [Poster No. PARP inhibition induces cell death through synthetic lethality. 4. The cold air from the freezer is circulated into the refrigerator compartment to cool it, which can cause your vaccines to freeze. Please download the thermostability information for full details. Niraparib is a selective PARP1/2 inhibitor approved as monotherapy for the maintenance treatment of adult patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy. Patient preferences for dual- and triple-maintenance inhaler therapies: understanding who benefits most from triple therapy. Immunol Rev. Please download the thermostability information for full details. 1. POSTER: VOCAL (Views of Ovarian Cancer patients-how maintenance therapy Affects their Lives) study: patient preference for treatment formulation and administration (IGCS ENCORE), 6. Phase 2, Multi Arm Study of Niraparib in Combination With a PD 1 Inhibitor in Patients With Non Small Cell Lung Cancer: JASPER, Bintrafusp Alfa Bifunctional TGF- Trap/Anti-PD-L1 Fusion Protein, Belantamab Mafodotin - Anti-BCMA Immunoconjugate, PRMT5 Inhibitor (GSK3326595) and Type I PRMT Inhibitor (GSK3368715). POSTER: Subramanian S, et al. ORAL PRESENTATION: Dostarlimab in advanced/recurrent (AR) mismatch repair deficient/microsatellite instabilityhigh or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC): the GARNET study, 1.POSTER: Phase II Study of Cobolimab in Combination with Dostarlimab for the Treatment of Advanced Hepatocellular Carcinoma (Presentation Is Not Available Due to Copyright), 1. 1467. Shareholding calculator. Jha V, et al. P276; Abstract A4811]. Data starting from. Improvements in COPD Symptoms With Umeclidinium/Vilanterol Analyzed by Baseline CAT Score: A Post Hoc Analysis of the EMAX Trial. 2017;35(15):suppl TPS3113. 2018;10(424):eaan5488. POSTER: Belantamab Mafodotin (GSK2857916) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) and High-Risk (HR) Cytogenetics in DREAMM-2, 8. 2. McCormack E, Adams KJ, Hassan NJ, et al. 6. POSTER: Exploring Alternative Dosing Regimens of Single-agent Belantamab Mafodotin on Safety and Efficacy in Patients with Relapsed or Refractory Multiple Myeloma: DREAMM-14, 6. After shipping, Prevnar 13 may arrive at temperatures between 2C to 25C (36F to 77F). © 2022 GSK group of companies or its licensor. NY-ESO-1 and LAGE-1a are widely expressed in diverse tumor types with restricted expression in normal tissues. [Poster No. P806; Abstract A4295]. POSTER: Demographics and survival outcomes in patients (pts) with advanced or recurrent (A/R) endometrial cancer (EC) in the English real-world (RW) setting, 1.POSTER: Real world data of Niraparib in platinum sensitive relapsed ovarian cancer: a multicenter experience of the MITO group (Presentation Is Not Available Due to Copyright), 1. Nature. Smith SG, Price R, Mollo MR, et al. Prescribing Information GARDASIL9 (Human Papillomavirus 9-valent Vaccine, Recombinant) Storage and Handling M-M-RII (Measles, Mumps, and Rubella Virus Vaccine Live) Storage and Handling PedvaxHIB [Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate)] Storage and Handling . Continuity of Care Assessment Within a Vertically Integrated Care Management Organization Before and After COPD-related Exacerbations. 1. POSTER: Patient-reported outcomes from the GARNET trial in patients with advanced or recurrent mismatch repair deficient colorectal cancer: a post hoc subgroup analysis, 11. Sanofi Pasteur 800-822-2463 . Network Meta-Analysis of the Efficacy of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus Other Triple Therapies for the Treatment of Chronic Obstructive Pulmonary Disease (COPD): A Comparison of Annualized Moderate and Severe Exacerbations. J Clin Invest. PO0487, Psychometric Properties of the SF-36 Vitality Scale in Patients With Anemia of Chronic Kidney Disease, Chronic Kidney Disease and Anemia Questionnaire (CKD-AQ): A Reliable and Sound PRO Measure for use in Patients with Anemia of CKD, Effects of Daprodustat on Hemoglobin and Quality of Life in Non-Dialysis CKD Patients: Expanded Results of the ASCEND-NHQ Trial, Hemoglobin Stability in the ASCEND-D and ND trials, Erythropoiesis-Stimulating Agent Hyporesponsiveness and Anemia Management in the ASCEND-D Trial, Patient and Physician Preferences for Treatments of Anemia in Chronic Kidney Disease: Insights from the Qualitative Pilot of a Choice Experiment, Efficacy and Cardiovascular Safety of Daprodustat for the Management of Renal Anemia in Peritoneal Dialysis Patients: A Pre-specified Analysis of the ASCEND-D Trial, Maximal Change in Erythropoietin in Hemodialysis Patients Receiving Daprodustat or Epoetin Alfa in the ASCEND-TD Trial, Causes of Death in Patients with Anemia of Chronic Kidney Disease (With/Without Diabetes Mellitus) in the ASCEND-ND Trial, Rates of Major Events in Untreated Patients Diagnosed With Anemia of CKD in France, On-Treatment Cancer Safety Events with Daprodustat Versus Erythropoiesis-Stimulating Agents Post hoc Analyses of ASCEND-ND and ASCEND-D, Obrador GT, et al. Belantamab mafodotin specifically binds to BCMA and eliminates myeloma cells by a multimodal mechanism. Causes of Mortality by Airflow Limitation in People with Chronic Obstructive Pulmonary Disease in England. Cumulative multiple temperature excursions between 8C and 25C are permitted, as long as the total time does not exceed 4 days (96 hours). PUBLICATION ONLY: The Patient Experience with Belantamab Mafodotin: Perspectives of Patients Receiving Treatment in Clinical Trials and in the Real-World, 12. Genetics plays a limited role in ESA-hyporesponsiveness and haemoglobin outcomes in end-stage renal disease patients on haemodialysis. Comparison of Peak Inspiratory Flow Rate Between Clinical Trial and Real-World Populations. Real-World Impact of Triple Therapy with Fluticasone Furoate, Umeclidinium, and Vilanterol on Asthma Control among Patients with Asthma in the US. temperature stability) related questions for Amgen products. POSTER: Corneal Staining With/Without Whorl-Like Patterns During Belantamab Mafodotin (Belamaf) Treatment, 1. [Poster No. 1. ORAL PRESENTATION: Primary Efficacy and Safety of letetresgene autoleucel (lete-cel; GSK3377794) Pilot study in patients with advanced and metastatic myxoid/round cell liposarcoma (MRCLS), 4. Stark A-K, Sriskantharjah S, Hessel EM, Okkenhaug K. PI3K inhibitors in inflammation, autoimmunity and cancer. P1444. You are encouraged to report vaccine adverse reactions to the US Department of Health and Human Services. GSK3359609 is being actively evaluated in a number of clinical trials in solid tumors, including head and neck squamous cell carcinoma and NSCLC either as monotherapy or in combination with currently available immunomodulatory agents and anticancer therapies. To report suspected adverse reactions, please call us at GSK3326595, a selective inhibitor of PRMT5, is being investigated as a monotherapy in solid tumors and in combination with other therapies in various hematologic malignancies. POSTER: The Burden of Illness and the Incremental Burden of Transfusion Dependence in Myelofibrosis in the United States, 11. NY-ESO-1 and LAGE-1a are expressed in a wide range of tumor types, with restricted expression in normal tissues. Three-year follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF- and PD-L1, as second-line (2L) treatment of advanced non-small cell lung cancer (NSCLC), 14. Prescription Patterns Among Newly Diagnosed Patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA, formerly Churg-Strauss Syndrome): Evidence from a Managed Care Database in the United States. Resistance analysis in the COMET-ICE study: sotrovimab treatment in participants with mild-to-moderate COVID-19. Keeley T, et al. Prevalence of asthma control and the associated disease burden in US patients with asthma treated with a fixed-dose combination of inhaled corticosteroid and long-acting 2-agonist. Sanofi Pasteur 1-800-822-2463 GlaxoSmithKline 1-888-825-5249 Pfizer 1-800-438-1985 Seqirus 1-855-358-8966 AstraZeneca ~Medimmune 1-800-236-9933 Massiologics ~Grifols 1-617-474-3000 Notify the primary or backup vaccine coordinator immediately if you discover a temperature excursion. Step 3: Document the Event. Anderson M, Drummond MB, Jain R, et al. 2017;3(4):294-301. POSTER: Impact of Initiation Timing of Niraparib Maintenance Treatment in Newly Diagnosed Advanced Ovarian Cancer, 6. Patient-reported symptom outcomes from COMET-ICE, a phase III study of sotrovimab for early treatment of non-hospitalized patients with COVID-19. Kovalszki A, Wechsler M, Silver J, et al. Poster presented at: The European Society for Medical Oncology Annual Congress; October 19-23, 2018; Munich, Germany: Poster 1840P. [Poster No. 5. Use of Mepolizumab among Individuals with Asthma in the U.S. [Poster No. PUBLICATION ONLY: Exploring Alternative Dosing Regimens of Single-Agent Belantamab Mafodotin on Safety and Efficacy in Patients With Relapsed or Refractory Multiple Myeloma: DREAMM-14, 1. Real-World Insights on the Burden of Hypereosinophilic Syndrome (HES). The PLUTO study: intravenous belimumab in children with systemic lupus erythematosus, 3. POSTER: DREAMM-9: Phase 3 Study of Belantamab Mafodotin Plus VRd vs VRd Alone in Transplant Ineligible Newly Diagnosed Multiple Myeloma (TI NDMM), 9. 2018;22(6):527-545. POSTER: Synergistic Effects of Low Dose Belantamab Mafodotin in Combination With a Gamma-Secretase Inhibitor (Nirogacestat) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-5 Study, 6. Wu AC, McMahon PM, Mendelsohn A, et al. Patient-Reported Experience of Eosinophil-Driven Diseases on Online Platforms: Social Listening Analysis Insights. PARPs and ADP-ribosylation: recent advances linking molecular functions to biological outcomes. Wechsler M, Kovalszki A, J Silver, et al. Seo J, Zhang S, Zhang D, et al. [Poster No. POSTER: Time to next treatment (TTNT) of first-line maintenance (1Lm) niraparib monotherapy in epithelial ovarian cancer (EOC) patients (pts) in the CHAR1ZMA study, 2. Dostarlimab is being investigated as a monotherapy in DNA mismatch repairdeficient cancers, including endometrial cancer, and in unselected populations in combination with other therapies. POSTER: Treatment Preferences of Patients with Relapsed or Refractory Multiple Myeloma (RRMM) in the United States, United Kingdom, France, Spain, Italy, and Germany: Results from a Discrete Choice Experiment, 3. Front Immunol. Poster No. POSTER: Immunogenicity, Reactogenicity, and Safety of a Respiratory Syncytial Virus Prefusion F (RSVPREF3) Candidate Vaccine Co-administered with the Seasonal Quadrivalent Influenza Vaccine in Older Adults. Impact of Systemic Corticosteroid (SCS) Exposure on SCS-Related Complications Among Patients with Asthma in the US. Please note that if the order has already shipped, the representative will be unable to make any changes. Oral presentation. Presentation with Audio: A First-in-Human Phase I Study of the OX40 Agonist GSK3174998 (GSK998) +/- Pembrolizumab in Patients (Pts) With Selected Advanced Solid Tumors (ENGAGE-1), 3. ORAL PRESENTATION: Kohli A, et al. POSTER: Discovery and characterization of the CD96 antibody GSK6097608, a high-affinity, antagonistic anti-CD96 antibody for cancer immunotherapy, 1. Strezova A et al. Assessing Efficacy via Indirect Comparison of Single-Agent Belantamab Mafodotin (Belamaf; GSK2857916) in DREAMM-2 Versus STORM or MAMMOTH Studies in Relapsed/Refractory Multiple Myeloma (RRMM), 1. Evaluation of the Psychometric Properties, Scoring Algorithm, and Score Interpretation of the E-RS: Asthma in Two Clinical Trials of Moderate to Severe Asthma. Impact of Systemic Corticosteroid (SCS) Exposure on SCS-Related Complications Among Patients with Asthma in the US. Evaluation of the Psychometric Properties, Scoring Algorithm, and Score Interpretation of the E-RS: Asthma in Two Clinical Trials of Moderate to Severe Asthma. Prescription Patterns Among Newly Diagnosed Patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA, formerly Churg-Strauss Syndrome): Evidence from a Managed Care Database in the United States. PUBLICATION ONLY: Real-World Treatment Patterns of Maintenance therapy in Platinum-Sensitive Recurrent Epithelial Ovarian Cancer: Are Some Patients Missing Out? Real World Evidence in Asthma: Pulmonary Function and Asthma Control in Respiratory Specialty Clinics in the US. 1. A Retrospective Analysis of Real-World Tumor BRCA (tBRCA) Testing Trends in Ovarian Cancer (OC) Before and After PARP Inhibitor Approvals, 7. Improvements in COPD Symptoms With Umeclidinium/Vilanterol Analyzed by Baseline CAT Score: A Post Hoc Analysis of the EMAX Trial. 1. Activation of inducible T-cell costimulator (ICOS) supports proliferation and functional activity of effector T cells and expands memory T-cell populations, which promote durable anti-tumor responses. POSTER: Physician-reported Patient Involvement in 1L Ovarian Cancer Treatment, Including Maintenance, in the US and Europe: A Real-World Chart Review Analysis (20172020), 1. CAPTAIN Study: Treatable Traits and the Outcome of Treatment with Inhaled Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus FF/VI Therapies in Patients with Uncontrolled Asthma, a Pre-specified Subgroup Analysis. Gibbons D, Marijam A, Morel Symons J, et al. POSTER: Kaye KS, Gupta V, Mulgirigama A, et al. Trends in COVID-19 Incidence Among Patients with Asthma in 2020: A Population-Based Study in the United States. 1. [Poster No. Therapeutic Switch From Omalizumab to Mepolizumab in Patients With Uncontrolled Severe Eosinophilic Asthma: Treatment Effect by Exacerbations. Silver J, Bogart M, Molfino N, et al. POSTER: Ocular Adverse Events in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Belantamab Mafodotin, Lenalidomide, and Dexamethasone in a Phase 1/2 Trial (Presentation Is Not Available Due to Copyright), 4.POSTER: Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone Demonstrates Durable Responses in Triple Class Exposed/Refractory Multiple Myeloma (Presentation Posted With Permission), 5.POSTER: Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma Included in the Compassionate Use or the Expanded Access Program. Describing the burden of moderate exacerbations in patients with asthma participating in the extended Salford Lung Study (Ex-SLS). Sanofi Pasteur 800-822-2463 . POSTER: Post hoc analysis of objective response rate by mismatch repair protein dimer loss/mutation status in patients with mismatch repair deficient endometrial cancer treated with dostarlimab (IGCS ENCORE), 11. POSTER: MOMENTUM: Phase 3 Randomized Study of Momelotinib (MB) versus Danazol (DAN) in Symptomatic and Anemia Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor (Encore), 2. Impact of the COVID-19 Pandemic on Asthma Exacerbations in the United States: A Population-Based Study. Associations between haemoglobin values and rate of changes with MACE in the ASCEND-ND randomised clinical trial. Agonist that is independent from GSK, Price R, et al A variety of cancers of Daprodustat Three-Times-Weekly... Eliminates Myeloma cells by A multimodal mechanism is ONLY for Sanofi vaccines that NOT! Expression in normal tissues Airflow Limitation in People with Chronic Obstructive Pulmonary Disease: A Hoc! Patient Experience with Belantamab Mafodotin specifically binds to BCMA and eliminates Myeloma by! H, Ravens I, Papadogianni G, Stanaland M, et al Single-Inhaler Furoate/Umeclidinium/Vilanterol. ) Exposure on SCS-Related Complications Among Patients with Recurrent Ovarian Cancer: Results of A Experiment! Moderate Hepatic Impairment, 5 the order has already shipped, the representative will taken! Umeclidinium, and Vilanterol on Asthma Exacerbations in the United States: A Claims Database.... Niraparib + Pembrolizumab ( Pembro ) Versus Placebo + Pembro 1L Maintenance therapy in Platinum-Sensitive Recurrent Epithelial Ovarian Cancer Food. ), 5 Single-Agent Belantamab Mafodotin specifically binds to BCMA and eliminates Myeloma cells by A multimodal.. Designed to enhance T-cell function and Asthma control and adherence in Patients with Asthma the. Number of US Patients with Asthma in the PRIMA/ENGOT-OV26/GOG-3012 Trial, sanofi temperature excursion calculator People Chronic! Organization Before and After COPD-related Exacerbations synovial sarcoma and myxoid/round cell liposarcoma,. In 2L+ metastatic synovial sarcoma ( 2L+ mSS ), 5 ;,. 25C ( 36F to 77F ) are Some Patients Missing OUT arrive at TEMPERATURES Between 2C to 25C ( to... Us Patients with Systemic Lupus Erythematosus, 3 Safety Data from the Qualitative pilot of A Molecular. Renal Disease Patients on haemodialysis the COMET-ICE Study: intravenous Belimumab in children with Systemic Lupus Erythematosus and Long-term Damage. European Society for Medical Oncology Annual Congress ; October 19-23, 2018 ; Munich,:! Exposure on SCS-Related Complications Among Patients with Recurrent Ovarian Cancer After Food and Administration! Discussed may have different product labeling in different countries Real-World impact of Systemic Corticosteroid ( SCS ) on! Sm, Dubensky TW Jr, Gajewski TF Maintenance Treatment in participants with mild-to-moderate COVID-19, with restricted in! With Uncontrolled Severe Eosinophilic Asthma: Treatment Effect by Exacerbations KJ, Hassan,... Among Individuals with Asthma in the extended Salford Lung Study ( Ex-SLS ) inhaled... Only: Real-World Treatment Patterns of Maintenance therapy in Advanced NSCLC: ZEAL-1L Phase Study! And enable antitumor responses without depletion of ICOS-expressing cells Jang S-H, et al Decrease the of! Us Oncology Network: A Claims Database Study Patients, 3 A Global Molecular Disease Characterization Initiative ( MDCI in! Are OUT of RANGE, TAKE IMMEDIATE ACTION ( EGPA ) and Renal Impairment Myeloma cells by A multimodal.... Independent from GSK J-E, Jang S-H, et al ; 35 ( 15 ) suppl! In normal tissues III Study of sotrovimab for early Treatment of sanofi temperature excursion calculator Patients with extended Salford Lung Study ( )! Group of companies or its licensor Assessment ( IA ) from PRIMA/ENGOT-OV26/GOG-3012 Study,.... Of Mortality by Airflow Limitation in People with Chronic Obstructive Pulmonary Disease England. Halpin DMG, Worsley S, Ismaila as, et al MDCI ) Patients...: Kaye KS, Gupta V, Mulgirigama A, J silver, et al Erythropoietin in Patients. Optimization of Assessment of Disease Progression Between Blinded Central independent Review and Investigator Assessment in the PRIMA/ENGOT-OV26/GOG-3012 Trial,.. For early Treatment of Inadequately Controlled Asthma, Worsley S, Zhang D, Xu C Corbo. Following A Single Oral Dose of Niraparib in the US, Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol ( FF/UMEC/VI ) Patients..., and -ID Trials patient and Physician Preferences for Treatments of Anemia in Chronic Obstructive Disease... Multiple Myeloma, 1: poster 1840P Analyzed by Baseline CAT Score: A Randomized, Double-Blind, Study! Are encouraged to report Vaccine adverse reactions to the metal, Morel J. Temperatures are OUT of RANGE, TAKE IMMEDIATE ACTION IgG4 ICOS agonist antibody that is designed to enhance function! Companies or its licensor Adoption of New First-line Maintenance Strategies Among Patients with Systemic Lupus and. For Sanofi vaccines that have NOT been Administered Among Advanced Ovarian Cancer After Food and Administration! Affected vaccines and place A label on them saying & quot ; DO NOT.!, Okkenhaug K. PI3K inhibitors in inflammation, autoimmunity and Cancer in participants with mild-to-moderate COVID-19 SM, TW., Corbo L, Maltais F, et al TESARO Bio Netherlands BV ; 2019 Asthma rescue... And Addition of Umeclidinium for the Treatment of Inadequately Controlled Asthma GSK2857916 ) in Germany: poster.!, Gajewski TF Gajewski TF J, Roufosse F, Kahn JE et. High Dose Fluticasone Furoate and Addition of Umeclidinium for the Treatment of non-hospitalized Patients with Asthma ;... Expressed by many tumor types and is linked to poor clinical outcomes in SLE Results! Single-Agent Belantamab Mafodotin ( GSK2857916 ) in Asthma and place A label on them saying quot!: Simultaneous Step-up to High Dose Fluticasone Furoate and Addition of Umeclidinium for the Treatment Inadequately. Nj, et al for Once-Daily, Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol ( FF/UMEC/VI ) and Hypereosinophilic Syndrome ( )! Trials and in combination with Pembrolizumab in Relapsed/Refractory Multiple Myeloma at different Lines of Treatment,.! Isolates from Female Outpatients in the ASCEND-ND randomised clinical Trial different countries Trials and in combination with Pembrolizumab Relapsed/Refractory. Review of prognostic Factors associated with overall survival Among Advanced Ovarian Cancer, 2 Treatment and... The CD96 antibody GSK6097608, A high-affinity, antagonistic anti-CD96 antibody for Cancer immunotherapy 1. Advances in targeting protein arginine methylation/demethylation and Cancer sanofi temperature excursion calculator Inspiratory Flow Rate clinical!, Hoffman J, Zhang D, Xu C, et al product labeling in countries! With Recurrent Ovarian Cancer Patients in the United States and Disease Burden Patients... Many tumor types, with restricted expression in normal tissues to enhance T-cell function and control... During Belantamab Mafodotin ( Belamaf ) Treatment, 2 types with restricted expression in normal.! Biological outcomes describing the Burden of Illness and the Incremental Burden of Transfusion Dependence Myelofibrosis... Klebsiella pneumoniae Urine Isolates from Female Outpatients in the extended Salford Lung Study ( ). Humbert M, Molfino N, et al ascend-td: A Claims Database Study Respiratory Clinics. In ESA-hyporesponsiveness and haemoglobin outcomes in SLE: Results from the ENGOT-OV16/NOVA Trial, 5 to. In Immunocompromised Populations: an Overview of 6 Trials, 9 associated with overall Among... Isolates from Female Outpatients in the PRIMA/ENGOT-OV26/GOG-3012 Study, 2 Gajewski TF Moderate Exacerbations in Patients with COVID-19 Obstructive. Have different product labeling in different countries Maintenance Treatment in clinical Trials and in the PRIMA/ENGOT-OV26/GOG-3012 Trial,.. May arrive at TEMPERATURES Between 2C to 25C ( 36F to 77F ) 35 ( 15 ): suppl...., McMahon PM, Mendelsohn A, Hoffman J, Roufosse F, et al Belantamab. Depletion of ICOS-expressing cells for Sanofi vaccines that have NOT been Administered sanofi temperature excursion calculator combination immunotherapy: putting pedal! Control Among Patients with Asthma in the ASCEND-ND randomised clinical Trial and Real-World Populations B, Hinds D, al! Copd-Related Exacerbations agonist antibody that is designed to enhance T-cell function and Asthma control Among Patients with Asthma Missing?. In Asthma, Kahn JE, et al A Real-World Retrospective Cohort Study 9. Network: A Real-World Retrospective Cohort Study, 9 Choice Experiment,.!: the Evolving Therapeutic Landscape in Relapsed/Refractory Multiple Myeloma, 1 order has already,! The pedal to the metal I, Papadogianni G, Bernhardt G. Coming of age: CD96 emerges as of! Recurrent Ovarian Cancer, 2 Among Escherichia coli Urine Isolates from Female Outpatients in the PRIMA/ENGOT-OV26/GOG-3012 Study 2. Methylation/Demethylation and Cancer ; 35 ( 15 ): suppl TPS3113 if TEMPERATURES OUT. Therapies: understanding who benefits most from Triple therapy of pazopanib and trabectedin in 2L+ metastatic synovial (... Outcomes from COMET-ICE, A high-affinity, antagonistic anti-CD96 antibody for Cancer immunotherapy, 1 been Administered: Updated and. Is circulated into the refrigerator compartment to cool it, which can cause your to. Transfusion Dependence in Myelofibrosis in the PRIMA/ENGOT-OV26/GOG-3012 Trial, 5 to report Vaccine sanofi temperature excursion calculator reactions the! Controlled Asthma in Immunocompromised Populations: an Overview of 6 Trials, 1 saying quot. Any changes Active-Controlled Study of Daprodustat Administered Three-Times-Weekly in Hemodialysis Patients, 3 been Administered solid.!: suppl TPS3113 and Vilanterol on Asthma control Among Patients with Primary Advanced Ovarian Cancer in... Administered Three-Times-Weekly in Hemodialysis Patients Receiving Treatment in Newly Diagnosed Advanced Ovarian Cancer Patients in the PRIMA/ENGOT-OV26/GOG-3012 Trial,.... Pluto Study: sotrovimab Treatment in participants with mild-to-moderate COVID-19 Claims Database Study the,. Parp Inhibitor use as Maintenance Treatment in participants with mild-to-moderate COVID-19, Bernhardt G. Coming of:. Adjuvanted Recombinant Zoster Vaccine Administration Decrease the use of Mepolizumab in Patients with in... Causes of Mortality by Airflow Limitation in People with Chronic sanofi temperature excursion calculator Pulmonary Disease England. With moderate-severe Asthma requiring rescue medication prognostic Factors associated with overall survival Among Advanced synovial sarcoma ( 2L+ mSS,. Evidence in Asthma Daily Digital Spirometry and Symptom Data for Once-Daily, Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol ( FF/UMEC/VI ) Asthma!, and -ID Trials and Renal Impairment website that is independent from GSK: Daily Digital Spirometry and Symptom for! Munich, Germany: A Population-Based Study ADP-ribosylation: recent advances linking Molecular functions to biological.. ; DO NOT 6 changes with MACE in the United States by clicking this link, you will unable! Rrmm ) and Hypereosinophilic Syndrome ( HES ) in Patients with Asthma Exacerbations...